CO-DIAGNOSTICS INC (CODX) Stock Fundamental Analysis
USA - NASDAQ:CODX - US1897631057 - Common Stock
0.3313 USD
-0.04 (-10.94%)
0.344 USD
+0.01 (+3.83%)
We assign a fundamental rating of 4 out of 10 to CODX. CODX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While CODX has a great health rating, there are worries on its profitability. CODX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CODX has reported negative net income.
In the past year CODX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CODX reported negative net income in multiple years.
In multiple years CODX reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -77.46%, CODX is not doing good in the industry: 73.55% of the companies in the same industry are doing better.
With a Return On Equity value of -87.49%, CODX is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.46% | ||
| ROE | -87.49% | ||
| ROIC | N/A |
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CODX (39.61%) is worse than 66.67% of its industry peers.
CODX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CODX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
2. Health
2.1 Basic Checks
CODX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CODX has more shares outstanding
Compared to 5 years ago, CODX has more shares outstanding
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.87, we must say that CODX is in the distress zone and has some risk of bankruptcy.
CODX has a Altman-Z score (-1.87) which is comparable to the rest of the industry.
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.87 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
CODX has a Current Ratio of 4.12. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
CODX has a better Current ratio (4.12) than 71.43% of its industry peers.
CODX has a Quick Ratio of 3.83. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.83, CODX is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.05% over the past year.
The Revenue for CODX has decreased by -42.52% in the past year. This is quite bad
Measured over the past years, CODX shows a very strong growth in Revenue. The Revenue has been growing by 79.52% on average per year.
EPS 1Y (TTM)22.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-76.6%
3.2 Future
CODX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.59% yearly.
CODX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 171.12% yearly.
EPS Next Y33.65%
EPS Next 2Y32.18%
EPS Next 3Y24.07%
EPS Next 5Y28.59%
Revenue Next Year-87.61%
Revenue Next 2Y-59.63%
Revenue Next 3Y111.18%
Revenue Next 5Y171.12%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CODX. In the last year negative earnings were reported.
Also next year CODX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CODX's earnings are expected to grow with 24.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.18%
EPS Next 3Y24.07%
5. Dividend
5.1 Amount
No dividends for CODX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.3313
-0.04 (-10.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.94%
Inst Owner Change-0.83%
Ins Owners7.88%
Ins Owner Change5.49%
Market Cap15.95M
Revenue(TTM)3.92M
Net Income(TTM)-35.99M
Analysts80
Price Target2.04 (515.76%)
Short Float %0.25%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.16%
Min EPS beat(2)28.7%
Max EPS beat(2)63.63%
EPS beat(4)3
Avg EPS beat(4)23.36%
Min EPS beat(4)-3.81%
Max EPS beat(4)63.63%
EPS beat(8)5
Avg EPS beat(8)-0.54%
EPS beat(12)7
Avg EPS beat(12)-29.57%
EPS beat(16)10
Avg EPS beat(16)-16.2%
Revenue beat(2)1
Avg Revenue beat(2)-40.16%
Min Revenue beat(2)-86.85%
Max Revenue beat(2)6.54%
Revenue beat(4)2
Avg Revenue beat(4)-18.44%
Min Revenue beat(4)-86.85%
Max Revenue beat(4)67.62%
Revenue beat(8)4
Avg Revenue beat(8)192.06%
Revenue beat(12)4
Avg Revenue beat(12)109.7%
Revenue beat(16)6
Avg Revenue beat(16)78.9%
PT rev (1m)0%
PT rev (3m)-63.64%
EPS NQ rev (1m)8.57%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)2.65%
EPS NY rev (3m)31.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 15.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.39 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.02
BVpS0.85
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.46% | ||
| ROE | -87.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.61% | ||
| FCFM | N/A |
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
F-Score2
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 57.84% | ||
| Cap/Sales | 73.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.83 | ||
| Altman-Z | -1.87 |
F-Score2
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)92.34%
Cap/Depr(5y)204.81%
Cap/Sales(3y)14.45%
Cap/Sales(5y)9.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y33.65%
EPS Next 2Y32.18%
EPS Next 3Y24.07%
EPS Next 5Y28.59%
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-76.6%
Revenue Next Year-87.61%
Revenue Next 2Y-59.63%
Revenue Next 3Y111.18%
Revenue Next 5Y171.12%
EBIT growth 1Y-0.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-124.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.92%
OCF growth 3YN/A
OCF growth 5YN/A
CO-DIAGNOSTICS INC / CODX FAQ
What is the ChartMill fundamental rating of CO-DIAGNOSTICS INC (CODX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CODX.
Can you provide the valuation status for CO-DIAGNOSTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to CO-DIAGNOSTICS INC (CODX). This can be considered as Overvalued.
How profitable is CO-DIAGNOSTICS INC (CODX) stock?
CO-DIAGNOSTICS INC (CODX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CODX stock?
The Earnings per Share (EPS) of CO-DIAGNOSTICS INC (CODX) is expected to grow by 33.65% in the next year.